908 Devices (MASS) Cash from Financing Activities (2020 - 2026)
908 Devices' (MASS) quarterly Cash from Financing Activities came in at -$2.2 million in Q1 2026, down 1047.09% year-on-year from $228911.7 in Q1 2025, and down 423.67% on a QoQ basis from -$414000.0 in Q4 2025.
908 Devices (MASS) Cash from Financing Activities (2020 - 2026) Analysis & Trends
908 Devices (MASS) has 7 years of Cash from Financing Activities data on file, last reported at -$2.2 million in Q1 2026.
- On a quarterly basis, Cash from Financing Activities fell 1047.09% year-over-year to -$2.2 million in Q1 2026; TTM through Mar 2026 was -$2.7 million, a 466.58% decrease from a year earlier, with the FY2025 full-year figure at -$697000.0, down 85.37% from the prior year.
- Cash from Financing Activities for Q1 2026 stood at -$2.2 million, down from -$414000.0 in the prior quarter.
- Over the last five years, Cash from Financing Activities for MASS reached as high as $529000.0 in Q4 2024 and fell as low as -$15.4 million in Q1 2023.
- Historically, Cash from Financing Activities has averaged -$1.1 million across 5 years, with a median of -$16000.0 in 2025.
- Across the five-year window, Cash from Financing Activities plunged 11931.54% in 2023 and jumped 456.84% in 2024, its largest moves.
- Year by year, Cash from Financing Activities stood at $411000.0 in 2022, then tumbled by 76.89% to $95000.0 in 2023, then soared by 456.84% to $529000.0 in 2024, then tumbled by 178.26% to -$414000.0 in 2025, then tumbled by 423.67% to -$2.2 million in 2026.
- Per Business Quant data, the three most recent Cash from Financing Activities figures were -$2.2 million in Q1 2026, -$414000.0 in Q4 2025, and -$16000.0 in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 181.32 Bn | 174.03 Bn | 6.27 Bn | 17.31 Bn |
| 2 | Stryker | 128.59 Bn | 125.71 Bn | 3.81 Bn | -1.51 Bn |
| 3 | Medtronic | 107.83 Bn | 98.61 Bn | 6.41 Bn | -888.00 Mn |
| 4 | Boston Scientific | 67.77 Bn | 66.32 Bn | 3.61 Bn | -260.00 Mn |
| 5 | Edwards Lifesciences | 48.13 Bn | 44.46 Bn | 1.29 Bn | -451.20 Mn |
| 6 | GE HealthCare Technologies | 28.44 Bn | 26.15 Bn | 1.98 Bn | 21.00 Mn |
| 7 | Dexcom | 28.41 Bn | 27.29 Bn | 750.30 Mn | -25.00 Mn |
| 8 | Smith & Nephew | 26.77 Bn | 26.20 Bn | - | - |
| 9 | Koninklijke Philips | 25.24 Bn | 22.11 Bn | 2.07 Bn | -26.93 Mn |
| 10 | 908 Devices | 269.51 Mn | 157.77 Mn | 6.88 Mn | -2.17 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2.17 Mn |
| Mar 31, 2026 | -2.17 Mn |
| Dec 31, 2025 | -414,000.00 |
| Dec 31, 2025 | -414,000.00 |
| Sep 30, 2025 | -16,000.00 |
| Sep 30, 2025 | -16,000.00 |
| Jun 30, 2025 | -78,000.00 |
| Jun 30, 2025 | -78,000.00 |
| Mar 31, 2025 | -189,000.00 |
| Mar 31, 2025 | -189,000.00 |
| Dec 31, 2024 | 529,000.00 |
| Dec 31, 2024 | 529,000.00 |
| Sep 30, 2024 | 23,000.00 |
| Sep 30, 2024 | 23,000.00 |
| Jun 30, 2024 | 367,000.00 |
| Jun 30, 2024 | 367,000.00 |
| Mar 31, 2024 | -1.30 Mn |
| Mar 31, 2024 | -1.30 Mn |
| Dec 31, 2023 | 95,000.00 |
| Dec 31, 2023 | 95,000.00 |